Bordetella pertussisis a highly communicable, acute, infectious respiratory disease that remains a cause of high morbidity and mortality among children worldwide. Reinfection is common in both previously vaccinated and nonvaccinated individuals. Asymptomatic and subclinical infections occur frequently among adolescents and adults. Macrolide agents are the drugs of choice for treatment and prophylaxis of pertussis. Acellular vaccine is available for infants, adolescents, and adults, including pregnant and postpartum women in the United States. Specific interventions are required to prevent the transmission of disease.